{"id":70747,"date":"2026-05-12T10:39:40","date_gmt":"2026-05-12T10:39:40","guid":{"rendered":"https:\/\/medsbase.com\/?post_type=product&p=70747"},"modified":"2026-05-21T07:14:10","modified_gmt":"2026-05-21T07:14:10","slug":"cagrilintide","status":"publish","type":"product","link":"https:\/\/medsbase.com\/nl\/cagrilintide\/","title":{"rendered":"Cagrilintide"},"content":{"rendered":"

<\/p>\n

\n

Quick Answer \u2014 What is Cagrilintide?<\/h3>\n

Cagrilintide<\/strong> (developmental code AM833) is a 37-amino-acid long-acting synthetic amylin analog developed by Novo Nordisk. It is the lead amylin-class research peptide in current metabolic research and the partner compound in the CagriSema combination (cagrilintide + semaglutide<\/a>), now in late-stage Phase 3 trials for obesity and type 2 diabetes. Plasma half-life ~159 hours enables once-weekly dosing. Supplied in 5\u00a0mg and 10\u00a0mg lyophilized vials for laboratory research use only.<\/p>\n<\/div>\n

Wat u krijgt bij MedsBase:<\/strong> Onderzoekskwaliteit lyofiliseerde peptiden \u00b7 HPLC \u226599% zuiverheid (COA op aanvraag) \u00b7 Discrete temperatuurstabiele verpakking \u00b7 Wereldwijde peptidekoerier \u00b7 1.400+ geverifieerd klantbeoordelingen<\/a><\/div>\n

\ud83d\udce6 Elke bestelling is gedekt door onze Reshipment Assurance Policy<\/strong><\/a> \u2014 als uw pakket niet binnen 20 werkdagen arriveert, sturen wij het opnieuw.<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Specificatie<\/th>\nDetail<\/th>\n<\/tr>\n<\/thead>\n
CAS-nummer<\/strong><\/td>\n1415456-99-3 (cagrilintide; commonly cited)<\/td>\n<\/tr>\n
Type<\/strong><\/td>\nLong-acting synthetic amylin analog (acylated 37-amino-acid peptide; calcitonin\/amylin receptor agonist; Novo Nordisk developmental code AM833)<\/td>\n<\/tr>\n
Moleculair gewicht<\/strong><\/td>\n~4,981 Da (with C20 fatty diacid acylation and intramolecular disulfide bridge)<\/td>\n<\/tr>\n
Structure<\/strong><\/td>\n37 amino acids based on the human amylin scaffold with substitutions that reduce amyloid-forming aggregation, an intramolecular Cys2\u2013Cys7 disulfide bridge required for receptor binding, and a C20 fatty-diacid acyl chain attached via a \u03b3-Glu-OEG-OEG spacer that drives strong reversible serum-albumin binding for the once-weekly half-life. C-terminus amidated.<\/td>\n<\/tr>\n
Form<\/strong><\/td>\nLyofiliseerd poeder (wit tot off-white)<\/td>\n<\/tr>\n
Zuiverheid<\/strong><\/td>\n\u226599% (HPLC geverifieerd, COA op aanvraag)<\/td>\n<\/tr>\n
Opslag<\/strong><\/td>\nLyofiliseerd: 2\u20138 \u00b0C (koelkast) voor werkvoorraad; \u221220 \u00b0C voor langdurige opslag van ongeopende flesjes. Gereconstitueerd: 2\u20138 \u00b0C, gebruik binnen ~30 dagen. Bescherm tegen licht. Vries de gereconstitueerde oplossing niet in en ontdooi deze niet.<\/td>\n<\/tr>\n
Oplosbaarheid<\/strong><\/td>\nBacteriostatic water (recommended) or sterile water for shorter use windows. Acylated peptides may dissolve more slowly than smaller unmodified peptides \u2014 allow extra equilibration time.<\/td>\n<\/tr>\n
Onderzoeksgebruik<\/strong><\/td>\nAlleen voor laboratoriumonderzoek. Niet voor humaan of veterinair diagnostisch of therapeutisch gebruik.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

<\/p>\n

What Is Cagrilintide?<\/h2>\n

Cagrilintide<\/strong> is a long-acting synthetic analog of amylin \u2014 a 37-amino-acid pancreatic peptide hormone co-secreted with insulin from beta cells and one of the principal endogenous regulators of postprandial glucose excursion, satiety signalling, and gastric emptying. Endogenous human amylin has a short plasma half-life (~13 minutes), poor pharmacokinetics, and a strong tendency to form amyloid aggregates (the same islet amyloid that accumulates in type 2 diabetic pancreas tissue). Cagrilintide was engineered by Novo Nordisk (developmental code AM833) to overcome each of these limitations: substitutions to reduce aggregation, an intramolecular disulfide bridge preserved for receptor binding, and a C20 fatty-diacid acyl chain attached via a \u03b3-Glu-OEG-OEG spacer that drives strong reversible binding to circulating serum albumin. The combined effect is a plasma half-life of approximately 159 hours (~6.5 days), enabling once-weekly subcutaneous research dosing.<\/p>\n

Cagrilintide has a mature molecular weight of approximately 4,981\u00a0Da including the acyl chain and disulfide bridge. The intramolecular Cys2\u2013Cys7 disulfide is essential for receptor binding \u2014 reduction of this bond converts the peptide into an inactive linear form. The fatty-acid tether is one carbon longer than semaglutide’s C18 acyl chain, producing the long half-life through the same albumin-binding mechanism. Cagrilintide is the most advanced compound in the renewed wave of amylin-pathway pharmacology, with the lead clinical programme being the CagriSema combination<\/strong> \u2014 cagrilintide 2.4\u00a0mg + semaglutide<\/a> 2.4\u00a0mg weekly \u2014 that completed the REDEFINE-1 (obesity) and REDEFINE-2 (T2DM) Phase 3 trials with body-weight reductions of approximately 20\u201323% over 68 weeks. Cagrilintide is niet goedgekeurd<\/strong> by the FDA, EMA, MHRA, or any other major regulator for human therapeutic use as a stand-alone agent or in combination. The research-grade cagrilintide sold here is supplied uitsluitend voor laboratoriumonderzoek<\/strong> and is not intended for human or veterinary administration.<\/p>\n

Mechanism of Action \u2014 Amylin Receptor Agonism Across CNS and Peripheral Sites<\/h2>\n

What makes cagrilintide pharmacologically distinctive from GLP-1 agonists is that it acts on a completely different receptor system \u2014 the amylin\/calcitonin receptor family \u2014 via three principal mechanisms<\/strong> documented in published research:<\/p>\n